Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)

ClinicalTrials.gov ID: NCT04168190

Public ClinicalTrials.gov record NCT04168190. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 7:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/Phase 2, Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine in Adults.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This Phase 1 and Phase 2 study will evaluate the safety, tolerability and immunogenicity of V116 when administered to adults. Phase 1 has no formal hypothesis. The primary hypotheses for Phase 2 are: V116 is noninferior to Pneumovax™23 as measured by the serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) for the common serotypes at 30 days postvaccination and that the serotype-specific OPA GMTs for the unique serotypes in V116 at 30 days postvaccination are statistically significantly greater following vaccination with V116 than those following vaccination with Pneumovax™23.

Study identification

NCT ID
NCT04168190
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Enrollment
600 participants

Conditions and interventions

Interventions

Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 5, 2019
Primary completion
Jul 11, 2021
Completion
Jul 11, 2021
Last update posted
Sep 15, 2022

2019 – 2021

United States locations

U.S. sites
20
U.S. states
13
U.S. cities
18
Facility City State ZIP Site status
Simon Williamson Clinic ( Site 0004) Birmingham Alabama 35211
Central Arizona Medical Associates ( Site 0003) Mesa Arizona 85206
Clinical Research of South Florida ( Site 0008) Coral Gables Florida 33134
Indago Research & Health Center, Inc ( Site 0011) Hialeah Florida 33012
Research Centers of America, LLC ( Site 0001) Hollywood Florida 33024
QPS Miami Research Associates ( Site 0016) Miami Florida 33143
L&C Professional Medical Research Institute ( Site 0009) Miami Florida 33144
Advanced Medical Research Institute ( Site 0010) Miami Florida 33174
Optimal Research ( Site 0006) Peoria Illinois 61614
Benchmark Research ( Site 0012) Metairie Louisiana 70006
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division ( Site 0018) Troy Michigan 48098
Meridian Clinical Research, LLC ( Site 0024) Norfolk Nebraska 68701
Wake Research Clinical Research Center of Nevada, LLC ( Site 0014) Las Vegas Nevada 89104
Meridian Clinical Research, LLC ( Site 0025) Endwell New York 13760
Rochester Clinical Research, Inc. ( Site 0002) Rochester New York 14609
PriMED Clinical Research ( Site 0021) Dayton Ohio 45419
Advanced Medical Research ( Site 0017) Maumee Ohio 43537
Kaiser Permanente Center for Health Research ( Site 0015) Portland Oregon 97227
Diagnostics Research Group ( Site 0013) San Antonio Texas 78229
Advanced Clinical Research ( Site 0022) West Jordan Utah 84088

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04168190, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 15, 2022 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04168190 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →